The company has thousands of trees and flowering shrubs in stock to supply an increase in demand for its unique ...

The leading life sciences reagents and instruments company is expected to announce its fiscal second-quarter earnings for ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

Detailed price information for Fibrogen Inc CS (FGEN-Q) from The Globe and Mail including charting and trades.

HONG KONG, Jan. 09, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has ...

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three ...

Panacea Bio share price has gained 7.27% in the past five sessions and nearly 21% in a month. However, the scrip has declined ...

Corteva Inc. (NYSE: CTVA) is one of the best fertilizer stocks to invest in. On December 16, the company confirmed a ...

The Phase 2a trial enrolled 35 IPF patients randomized in a 2:1 ratio to receive either GRI-0621 or placebo once daily for 12 weeks. A sub-study examined immune cells in bronchoalveolar lavage fluid ...

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in ...